Urology - urothelial cancer, Malmö
1 – 10 of 193
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study : a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial
- Contribution to journal › Article
-
Mark
The potential association between degree of mammographic spiculation and prognosis
- Contribution to journal › Article
-
Mark
Breast cancer and liver metastases: an imaging perspective on the potential of resectability
(2026) In Acta Radiologica
- Contribution to journal › Article
-
Mark
First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma—commentary on patient-reported outcomes in EV-302
- Contribution to journal › Debate/Note/Editorial
-
Mark
Emergency computed tomography in acute renal colic is essential for correct diagnosis and shortens time to treatment and stone-free status
- Contribution to journal › Article
-
Mark
Re : Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014
(2026) In European Urology Focus
- Contribution to journal › Letter
- 2025
-
Mark
Breast cancer recurrence in relation to mode of detection : implications on personalized surveillance
- Contribution to journal › Article
-
Mark
Pre-treatment metastatic biopsy : a step towards precision oncology for urothelial cancer
- Contribution to journal › Scientific review
-
Mark
The association between animal protein, plant protein, and their substitution with bladder cancer risk : a pooled analysis of 10 cohort studies
- Contribution to journal › Article
-
Mark
Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI) : a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study
- Contribution to journal › Article
